IOV

What IOV does

IOV (Istituto Oncologico Veneto - IRCCS) is a public Scientific Institute for Hospitalization and Care headquartered in Padova, Italy, specializing in comprehensive oncology services including cancer prevention, diagnosis, surgical and medical treatment, radiotherapy, and follow-up care. Founded in 2005 as part of the Regione Veneto healthcare system (SSSR), IOV operates three physical locations — Padova (Ospedale Busonera, headquarters), Castelfranco Veneto (Ospedale San Giacomo), and Monselice (radiotherapy) — and employs 501–1,000 staff with over 500 oncology researchers across four principal research lines: molecular oncology and innovative diagnostics, oncoimmunology and advanced cell therapies, innovative therapeutic strategies, and a high-resolution oncological registry. The institute's technology platform centers on multidisciplinary cancer care via PDTA pathways, robotic surgery (400+ procedures/year for prostate/bladder/kidney carcinoma), advanced liquid biopsy diagnostics, radiotherapy, and clinical trials across breast, sarcoma, melanoma, lung, and head/neck cancers, complemented by digital health services including an Electronic Health Record (Fascicolo Sanitario Elettronico) and the Firstline antimicrobial prescription app.

IOV's business model is a public-payor, grant-and-donation-funded hybrid rather than a commercial transactional model. The institute receives the majority of its operating revenue through Italian National Health Service (SSN) reimbursements and regional SSSR allocations for diagnostic, treatment, and hospitalization services provided to oncology patients at regulated public rates; secondary revenue streams include competitive research grants from the Italian Ministry of Health (over €1M for three projects in 2024 via Bando Ricerca Finalizzata), 5x1000 tax designation funds (€3,782,084.13 from 69,639 taxpayers in 2024, +16% YoY), and philanthropic donations from patient associations and foundations (e.g., €70,000 from Associazione Piccoli Punti for liquid biopsy equipment, €25,000 from APE-AVIS for leukemia research). The go-to-market motion is sales-led through the regional SSN referral infrastructure (CUP booking center, GP/specialist referrals), augmented by 10+ European research network memberships (OECI since 2010, EUREGHA since 2026, DIGICORE since 2023, ESTRO, APRE) that channel collaborative research funding and translational capabilities into the institute. Customer segments are horizontal across oncology patients, the cancer research community, and the regional organ/tissue donation network, with all clinical services delivered through public healthcare channels.

Name

IOV

Legal name

IOV Istituto Oncologico Veneto - IRCCS

Website

https://ioveneto.it

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

IOV (Istituto Oncologico Veneto - IRCCS) is a public Italian oncology research and treatment institute in Padova, providing cancer prevention, diagnosis, surgery, radiotherapy, and research across three Veneto locations, serving oncology patients via the Italian National Health Service with 500+ researchers.

Ownership category

akta.pro rank

Product category

Cancer Treatment Services

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Medical Laboratories (8071)

akta.pro primary industry

Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

akta.pro secondary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Oncology treatment services
• Cancer research institute
• Radiotherapy services
• Oncological surgery
• Clinical cancer trials

Headquarters

HQ city

Padova

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. National Health Service (SSN) Reimbursements: As a public healthcare institute (IRCCS), IOV receives funding through the Italian National Health Service for diagnostic, treatment, and hospitalization services provided to patients under the public healthcare system.
2. 5x1000 Tax Designation: IOV receives 5x1000 tax designation funds from Italian taxpayers who choose to allocate a portion of their income tax to support the institute. In 2024 campaign, this amounted to 3,782,084.13 euros from 69,639 taxpayer signatures.
3. Ministerial Research Funding: Competitive research grants from the Italian Ministry of Health through programs like Bando Ricerca Finalizzata. IOV received over 1 million euros to fund three research projects in 2024.
4. Donations and Philanthropy: Voluntary donations from individuals, associations, and foundations supporting cancer research and institute activities. Examples include Association Piccoli Punti (70,000 euros for liquid biopsy equipment), APE AVIS (25,000 euros for leukemia research), and various other donors.
5. Charitable Events and Fundraising: Revenue from charitable events like 'Tempesta' theatrical-musical performance supporting IOV research and care activities, organized with partners like Banca Prealpi SanBiagio.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Core offering

IOV is a public scientific institute for hospitalization and care (IRCCS) specializing in oncology, delivering cancer prevention, diagnosis, treatment, and follow-up services across the Veneto region. Its core offerings span multidisciplinary cancer care (surgery, chemotherapy, radiotherapy, robotic surgery), advanced diagnostics such as liquid biopsy, clinical trials, and translational research across four principal research lines. The institute operates three physical locations in Padova, Castelfranco Veneto, and Monselice, and provides digital health services, patient education, and organ/tissue donation coordination.

Product overview

IOV (Istituto Oncologico Veneto) is an IRCCS (Institute for Hospitalization and Scientific Research) oncology center offering a comprehensive cancer care ecosystem. The core offering centers on clinical trials and multidisciplinary cancer treatment spanning surgery, chemotherapy, radiotherapy, and follow-up care. Patient support services include the 'Nurse Response' hotline, extensive informational brochures, and the innovative 'L'Oncologia Spiegata' comic-based science communication program. Digital health infrastructure provides online appointment booking, electronic health record access, and report retrieval. The institution operates across three locations in Padova, Castelfranco Veneto, and Schiavonia, with a focus on translational research directly benefiting patient care.

Differentiator

Problem solved

Functional benefit

Products and services

• Multidisciplinary Cancer Care (PDTA) Multidisciplinary team-based oncology care with diagnostic-therapeutic-assistance pathways (PDTA) coordinating surgery, chemotherapy, radiotherapy, robotic surgery, and follow-up for oncology patients.
• Clinical Trials (Sperimentazioni Cliniche) A structured clinical research program conducting experimental treatments and therapeutic studies across multiple oncology specialties including breast cancer, sarcoma, melanoma, lung cancer, and head/neck cancers.
• Digital Health Services Online services including Electronic Health Record (Fascicolo Sanitario Elettronico), online appointment booking and cancellation, report retrieval, and payment services.
• Patient Education and Support Services Comprehensive patient support including the 'Nurse Response' service answering chemotherapy-related questions, informational brochures, and psychological support through psiconcologia.
• L'Oncologia Spiegata (Cancer Explained) A science communication initiative using comic strips and animated videos to explain cancer research and oncology concepts to patients and the general public, developed in collaboration with cartoonist Marco Gavagnin.
• Advanced Diagnostics (Liquid Biopsy) Advanced diagnostic technology for liquid biopsy analysis enabling minimally invasive cancer detection and monitoring through analysis of nucleic acids and molecular markers from biological samples, particularly useful for melanoma and other cancers.
• Organ and Tissue Donation Coordination Hospital transplantation coordination (COT) managing organ, cornea, and multi-tissue donations from deceased patients as part of the regional NITp transplant network.
• Robotic Oncological Surgery Robotic surgery for prostate, bladder, and kidney carcinoma treatment, with 400+ robotic surgeries performed annually.

Quantifiable outcome

• 3,782,084.13 euros raised through 5x1000 from 69,639 taxpayers in 2024
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

21 partnerships are on record, tiered core and minor.

• EUREGHA (European Regional and Local Health Authorities)coreStrategic or Co-development Partner · 1 January 2026European network representing regional and local health authorities. IOV joined in 2026, enabling privileged dialogue with EU institutions and direct contribution to debates on healthcare sustainability and innovation.
• DIGICOREcoreTechnology or Integration · 1 January 2023Strategic network focused on digital interoperability development in healthcare. Enables IOV to improve data quality, develop new data sources, share digital best practices, and promote innovative digital-based research methodologies.
• OECI (Organization of European Cancer Institutes)coreStrategic or Co-development Partner · 1 January 2010Network of excellence cancer institutes sharing advanced care models, strengthening translational research, and facilitating access to European funding. IOV member since 2010.
• APRE (Agenzia per la Promozione della Ricerca Europea)coreStrategic or Co-development Partner · 1 January 2010Agency supporting Italian participation in European research and innovation programs. Provides training and assistance for accessing EU funding. IOV member since 2010.
• ESTRO (European Society for Radiotherapy & Oncology)minorStrategic or Co-development PartnerEuropean radiotherapy society. IOV joined the scientific network in 2025, strengthening radiotherapy excellence.
• ELBS (European Liquid Biopsy Society)minorStrategic or Co-development PartnerEuropean society focused on liquid biopsy research and applications.
• EURADOS (European Radiation Dosimetry Group)minorStrategic or Co-development PartnerEuropean group for radiation dosimetry research.
• MELODI (Multidisciplinary European Low Dose Initiative)minorStrategic or Co-development PartnerEuropean initiative focused on low-dose radiation research.
• EARMA (European Association of Research Managers and Administrators)minorStrategic or Co-development PartnerEuropean association for research managers and administrators.
• Regione VenetocoreGTM or Marketing PartnerRegional government providing patronage for 'L'Oncologia Spiegata' educational project and overall institutional support.
• Comune di PadovaminorGTM or Marketing PartnerMunicipal partner including Progetto Giovani, supporting educational and community outreach programs.
• Assindustria VenetocentrominorGTM or Marketing PartnerIndustrial association partner in the Veneto region supporting educational outreach.
• Ordine Provinciale dei Medici Chirurghi e Odontoiatri - PadovaminorGTM or Marketing PartnerMedical association providing scientific endorsement for educational projects.
• CRI Comitato Veneto (Croce Rossa Italiana)minorGTM or Marketing PartnerItalian Red Cross Veneto committee as partner in community outreach.
• UISP Comitato provinciale di PadovaminorGTM or Marketing PartnerSports association partner for community engagement activities.
• APE - AVIS per il Progresso EmatologicominorGTM or Marketing PartnerBlood donation association supporting hematology research. Donated 25,000 euros for acute leukemia research in collaboration with IOV researchers.
• Associazione Piccoli Punti ETSminorGTM or Marketing PartnerMelanoma patient association. Donated 70,000 euros worth liquid biopsy equipment for the Integrated Liquid Biopsy Laboratory. 20-year partnership supporting melanoma diagnosis innovation.
• AIL - Associazione Italiana contro Leucemie, Linfomi e MielomaminorGTM or Marketing PartnerItalian Association against Leukemias, Lymphomas and Myeloma. Co-beneficiary of 'Tempesta' charity event.
• NITp - Nord Italia Transplant programcoreStrategic or Co-development PartnerNorthern Italy transplant network. IOV received 'Stella della Donazione' during their technical-scientific meeting. Part of regional organ donation network.
• Università di PadovacoreStrategic or Co-development PartnerUniversity of Padua collaborating on cancer research including T-ALL leukemia study published in Signal Transduction and Targeted Therapy journal. Joint research with Department of Surgical, Oncological and Gastroenterological Sciences.
• Città Sane - Rete italiana OMSminorGTM or Marketing PartnerItalian WHO Healthy Cities network as partner in community health initiatives.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Veneto Institute of Oncology IOV (peer reference — AOU Padova oncology): University of Padova (Azienda Ospedale-Università Padova) is IOV's primary academic and clinical collaborator within the Veneto region, with shared faculty and joint research outputs. Comparable as a regional Veneto oncology provider with academic research overlap.

Broad incumbents

• European Institute of Oncology (IEO): IEO is one of Italy's flagship IRCCS oncology centers in Milan with comprehensive cancer care, research, and clinical trials. Directly comparable as a peer Italian public scientific oncology institute with multidisciplinary cancer programs and EU network participation.
• IRCCS Ospedale San Raffaele: San Raffaele is a major Milanese IRCCS hospital with significant oncology, gene therapy, and clinical research programs. Comparable as an Italian IRCCS combining hospital care with research across multiple specialties including oncology.
• IRCCS Istituto Clinico Humanitas: Humanitas is a leading Italian IRCCS near Milan with strong oncology and translational research programs. Comparable as a private-not-for-profit Italian research hospital competing for the same talent, grants, and complex oncology cases.
• Fondazione IRCCS Istituto Nazionale dei Tumori (INT): INT Milan is Italy's largest cancer-focused IRCCS with extensive translational research, clinical trials, and inpatient oncology services. Directly comparable as a fellow Italian IRCCS with similar mission, scale, and funding profile.

Direct peers

• IFOM (FIRC Institute of Molecular Oncology): IFOM is a Milan-based molecular oncology research institute closely affiliated with Italian cancer centers. Comparable as an Italian oncology research entity with strong emphasis on molecular oncology and translational science — overlapping IOV's first principal research line.
• CRO Aviano (Centro di Riferimento Oncologico): CRO Aviano is a Friuli Venezia Giulia IRCCS dedicated to oncology with research and clinical trials. Comparable as a northeastern Italian regional cancer center with similar IRCCS structure and research-hospital hybrid model.

Others

• European Organisation for Research and Treatment of Cancer (EORTC): EORTC is a pan-European cancer clinical trial cooperative group that IOV researchers participate in through OECI/ESTRO membership. Comparable as an ecosystem enabler that IOV accesses for multi-center oncology trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/ioveneto
• Facebookfacebook.com/IOV.Istituto.Oncologico.Veneto
• LinkedInlinkedin.com/company/istituto-oncologico-veneto-iov-irccs
• Instagraminstagram.com/iov_istitutooncologicoveneto
• Xx.com/iov_irccs

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IOV